Biotech Company Plans Local Facility

BRADENTON -- Mark P. Famiglio, CEO of Cambryn Biologics (CB), a privately held Delaware corporation, announced the initiation of the commissioning of its state-of-the-art biological manufacturing facility located in Sarasota and Manatee County this week. Cambryn specializes in biologically-based raw material derived primarily from human plasma.

CB’s services include extraction and purification of the fractionated components of plasma, including but not limited to enzymes and proteins. Upon completion of its validation process as a cGMP facility (current-Good Manufacturing Practices), CB intends to provide biological contract manufacturing.

CB’s core customer base is domestic and international biopharmaceutical companies, research and development organizations, and universities that require biological cGMP grade components and material used in pre-clinical and clinical studies. The company says it plans to scale-up the facility for early commercial launch. CB’s commercial opportunity is directed to the biotherapeutic, diagnostic and veterinary market worldwide.

“Cambryn is fully funded and poised to meet the growing demand for biologic products.” said Valli Baldassano, President of  Cambryn. "With over 50 million dollars invested in its 75,000 square-foot U.S. facility, our team of highly skilled and experienced scientists and technologists expect major expansion and consequent employment opportunities over the next 24 months."

Marc Paquin, Chief Operating Officer for Cambryn, explained that the unique size and raw material flexibility of the facility will make it an ideal manufacturing environment for small and large organizations that need pilot-plant scale biological components. "Our current manufacturing capacity can be scaled to 35,000 liters/annually," said Paquin. "The facility also includes fully-equipped Quality Control and Process Development laboratories.”